Migraine

Migraine may be the most consequential disease that people are still told to walk off. It affects roughly one person in seven — about a billion people — runs strongly in families, and in the Global Burden of Disease studies ranks second among all causes of disability on Earth, and first among young women, who live with it at three times the rate of men. None of that describes “a bad headache.” It describes a neurological disease with its own machinery — machinery that science has now traced well enough to build drugs against, which is why migraine has become pain medicine’s biggest recent success story.

An attack is more than a headache

A migraine attack is a sequence, and the headache is its loudest middle chapter. Many attacks announce themselves a day early in the prodrome — yawning, food cravings, mood shifts, neck stiffness — driven by deep brain regions like the hypothalamus waking up first. About one in three people then experience aura: a slow electrical wave crossing the brain’s surface, felt most often as shimmering zigzags or a growing blind spot that spreads over twenty to sixty minutes before fading. The headache phase brings the signature: throbbing, often one-sided pain lasting hours to days, with a nervous system so amplified that light, sound, smells, and ordinary movement all hurt. And then the postdrome — the migraine hangover of fog and fatigue that costs many people another day. The prodrome hides a useful insight: some famous “triggers” are really early symptoms. Craving chocolate may not cause the attack — the attack, already underway, may be causing the craving.

The engine: a nerve, a peptide, a sensitive brain

For most of a century migraine was blamed on blood vessels stretching. The modern picture is neurological. The inherited part is a brain whose sensory networks sit closer to their tipping point. The attack part is traceable: the trigeminal nerve— the great sensory nerve of the head — activates and releases CGRP, a peptide that inflames the brain’s pain-sensitive coverings and drives the throbbing, movement-hating pain, while brainstem and thalamic circuits amplify every other sense. That specificity is the story: CGRP is not a metaphor but a molecule, and blocking it works — the arc told in full in biologics & gene-targeted therapy.

Triggers, honestly

Trigger lists are where migraine advice usually goes to die — everything from weather to wine gets blamed, and patients end up policing their lives. The evidence supports a humbler model: triggers are probabilistic, they stack, and they act on a brain whose threshold is already set by sleep, stress, hormones, and routine. The highest-yield moves are unglamorous: regularity — of sleep, meals, hydration, caffeine, and exercise — raises the threshold an attack has to clear. Sleep earns special mention: it is one of the few levers with mechanism and evidence on its side. A simple diary beats an internet trigger list — it finds your pattern, and sometimes reveals that a supposed trigger was the prodrome all along.

How it’s diagnosed — and the red flags

Migraine is a clinical diagnosis — there is no blood test or scan that shows it. The international criteria look for the pattern: attacks lasting hours to days, pain that throbs and favors one side, worsens with routine movement, and travels with nausea or with sensitivity to light and sound. A typical story needs no imaging. What changes the calculus are the red flags: a thunderclap headache reaching full force in seconds, a first severe headache after fifty, fever with a stiff neck, aura-like symptoms that include weakness or trouble speaking, symptoms that arrive suddenly rather than marching gradually, or a long-stable pattern that transforms. Those earn urgent evaluation — everything else earns a proper migraine plan.

How migraine is treated today

Acute treatment is a race: medications work best taken early, while the attack is still building. Anti-inflammatory painkillers genuinely help many attacks; the triptans — the first drugs ever designed from migraine’s biology, back in the 1990s — remain the workhorses; and the newer gepants and lasmiditan cover people whose attacks laugh at triptans or whose hearts shouldn’t meet them. Opioids, deliberately, have almost no place in routine migraine care. And one honest warning belongs in bold type: acute relief used on too many days a month, for months, can flip episodic migraine into a near-daily medication-overuse headache that the same pills no longer touch. Counting days is not pedantry — it is how you keep your rescue medicines working.

Prevention is where the revolution happened. When attacks claim several days a month, guidelines shift from rescuing to preventing: long-standing oral options — blood-pressure, seizure, and antidepressant medications with earned migraine evidence — plus, for chronic migraine, botulinum toxin injections. Since 2018 they have been joined by the CGRP monoclonal antibodies — monthly or quarterly injections that lower attack frequency with strikingly little side-effect baggage — and preventive gepants in tablet form. For many people these are the first treatments that feel designed for their disease, because they were. Which of any of this fits you — including wearable neuromodulation devices for those who prefer hardware to pharmacology — is a plan to build with your clinician, not a menu to self-serve.

What’s coming

The CGRP era proved that decoding a mechanism yields drugs; the field is now working the next peptides, with PACAP-blocking antibodies furthest along in trials for people CGRP drugs miss. The pipeline tracker follows the candidates; migraine research remains the clearest demonstration in all of pain medicine that the frontier pays out.

When to bring in a specialist

If migraine is costing you multiple days a month despite a fair acute-treatment plan, if prevention has never been discussed, or if you suspect the medication-overuse trap has already closed — that is the moment for specialist care: headache medicine and pain medicine both live here. Finding pain care near you explains how to start looking.